Dydrogesterone and other progestins in benign breast disease: an overview.

Abstract

Progestogens appear to have a dual effect on the cell cycle in breast cells and breast cancer cells. There is initially stimulation of mitotic activity. However, continuous application leads to cell apoptosis. This depends on type, dose and length of progestogen application in relation to estrogen action. In benign breast disease the use of progestogens results not only in reduction of mastodynia, but also a reduction in breast gland size and disappearance of nodularity proven by clinical examination and follow-up including breast ultrasound.

• Authors: Adolf E Schindler
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 283 Issue 2 Pg. 369-71 (Feb 2011) ISSN: 1432-0711 [Electronic] Germany
• PMID: 20383772 (Publication Type: Journal Article, Review)

Chemical References

• Progestins
• Medrogestone
• Dydrogesterone

Topics

• Breast Diseases (diagnostic imaging, drug therapy)
• Dydrogesterone (therapeutic use)
• Female
• Humans
• Medrogestone (therapeutic use)
• Progestins (therapeutic use)
• Ultrasonography